Switching Patients Off Bupropion in Japan: A Guide for Prescribers
Bupropion is not approved in Japan, so a patient who arrives on it has to be moved to something else, and the replacement follows the indication, not the molecule. There is no norepinephrine-dopamine reuptake inhibitor antidepressant on the Japanese market. This guide is written for two prescribers: the Japanese psychiatrist receiving the patient, and the overseas clinician planning the switch before departure. The patient-facing version is our Wellbutrin in Japan article.
Why is bupropion unavailable, and what can the patient bring?
It reached a Japanese Phase 3 study for depression and went no further. GlaxoSmithKline ran a Japanese program for major depressive disorder through Phase 3 (the fixed-dose study NCT01138007 completed in 2012), and no product followed. The Japanese Society of Mood Disorders' 2023 late-life depression guideline still lists it as unapproved when it cites the switch-versus-augment trials.
For import purposes it is an ordinary prescription medicine. Under the health ministry's personal import rules, a patient may carry up to one month's supply of a prescription drug without paperwork, and more with an import confirmation certificate (輸入確認証, yunyu kakunin-sho) obtained in advance (how the certificate works). That month is the window for the switch.
What was bupropion doing for this patient?
Ask this first; it decides everything below. Bupropion is prescribed for one of seven jobs, and the same patient often has two:
- Antidepressant monotherapy, chosen for its tolerability profile
- Fatigue, hypersomnia, or low drive as the target residual symptoms
- Avoiding sexual dysfunction that an SSRI caused earlier
- Avoiding weight gain
- Augmentation of an SSRI after partial response
- ADHD, either formally diagnosed or treated without the label (off-label, and third-line in the CADDRA guideline)
- Smoking cessation
What replaces it for each indication?
Every medicine below is approved in Japan, and doses are per the Japanese labels. One label limit to note: lithium is approved in Japan for mania only, so adding it to an antidepressant is off-label here.
| Job | Options in Japan | Evidence note |
|---|---|---|
| Antidepressant monotherapy | Any SSRI, duloxetine, venlafaxine, milnacipran, mirtazapine, vortioxetine | In STAR-D level 2, remission after switching to bupropion, sertraline, or venlafaxine was similar (18 to 25 percent on the HRSD-17) |
| Fatigue, hypersomnia, low drive | An SNRI first; avoid sedating options such as mirtazapine and trazodone | Bupropion beat SSRIs on residual hypersomnia and fatigue in a pooled analysis (Papakostas 2006); CANMAT 2016 lists bupropion for fatigue at level 1 and duloxetine for energy at level 2, and the 2023 update notes that energy and fatigue may respond better to SNRIs than SSRIs |
| Sexual side effects | Vortioxetine or mirtazapine; otherwise the lowest effective SSRI dose, avoiding paroxetine and escitalopram | Bupropion and mirtazapine did not differ from placebo on treatment-emergent sexual dysfunction in a meta-analysis (Serretti 2009); switching SSRI responders with sexual dysfunction to vortioxetine improved sexual function more than switching to escitalopram (Jacobsen 2015) |
| Weight | Vortioxetine or an SSRI other than paroxetine; not mirtazapine | Nothing available in Japan reproduces bupropion's mild weight loss; amitriptyline, mirtazapine, and paroxetine carry the highest weight-gain risk (Serretti 2010) |
| ADHD | Methylphenidate ER through the registration system (Concerta has been on limited shipment since September 2025), atomoxetine, guanfacine; all three carry adult labels. Lisdexamfetamine can be started only at ages 6 to 17 | Bupropion's adult ADHD effect is modest and low-certainty (SMD -0.50, Cochrane 2017); CADDRA ranks long-acting stimulants first-line and atomoxetine and guanfacine second-line, above bupropion's third-line place, so this is usually an upgrade |
| Smoking cessation | Varenicline (shipments resumed in Japan in October 2025 after the nitrosamine suspension), nicotine patch or gum | Varenicline outperforms bupropion head to head (OR 1.59, Cochrane 2013); bupropion and NRT were equally effective |
| Augmentation of an SSRI | Aripiprazole, brexpiprazole, lithium, mirtazapine add-on | CANMAT 2023 lists aripiprazole and brexpiprazole as first-line adjuncts, with bupropion second-line in the 2016 table; in CO-MED, escitalopram plus bupropion did not beat escitalopram alone |
Two conversions to avoid:
- Do not treat an SNRI as "bupropion with serotonin added." Venlafaxine and duloxetine are the closest functional neighbors for drive and fatigue, but they bring SSRI-type sexual and discontinuation effects that the patient may have left an SSRI to escape.
- Do not carry an undiagnosed ADHD job silently into an antidepressant. If bupropion was the ADHD treatment, assess it properly and treat it as ADHD.
How do you run the switch?
Cross-taper over two to four weeks. That is the usual window in the NHS Specialist Pharmacy Service's switching guidance; if the patient has taken bupropion for less than about four weeks, CANMAT 2023 allows a faster taper over two weeks or less. Bupropion is straightforward to discontinue: discontinuation symptoms are uncommon (CANMAT puts it in the lowest-risk group), it has no serotonergic activity, so overlapping it with an SSRI, SNRI, mirtazapine, or vortioxetine raises no serotonin syndrome concern, and its half-life of around 21 hours means a missed day during travel is not a problem.
The interaction that changes what you do is CYP2D6. Bupropion and its metabolites inhibit CYP2D6 for at least a week after the last dose, so co-prescribed substrates such as venlafaxine, risperidone, aripiprazole, and atomoxetine lose exposure as it clears. Atomoxetine is the one to plan around: its Japanese package insert lists CYP2D6 inhibitors under precautions for concomitant use and asks for unhurried titration. Keep atomoxetine at the starting dose while bupropion is still on board, and titrate only after it has cleared rather than during the overlap.
The practical sequence for an overseas prescriber is to start the replacement before departure, so the patient lands on a stable Japanese-available regimen with records in hand. For the receiving psychiatrist, the one-month carried supply is the cross-taper window; book the first follow-up inside it.
What should you expect after the switch?
Three things that the table above does not settle.
- Sexual dysfunction on the new drug: switch, do not add. The randomized evidence is for switching (vortioxetine over escitalopram in patients switched for SSRI-emergent dysfunction). Adjunctive aripiprazole has only a post hoc signal, its Japanese indication is augmentation for inadequate response rather than sexual dysfunction, and it brings akathisia and weight.
- ADHD symptoms surfacing after the switch. Bupropion is used off-label for adult ADHD and an SSRI does not cover that job. There is no frequency data to rank it, but the history can show attention problems that predated the depression; run the assessment and choose among the three adult-approved agents.
- Weight. Say in advance that no Japanese option is weight-negative, and weigh at baseline and monthly if mirtazapine is in the plan.
What should be monitored?
Mood, sleep, sexual function, weight, and blood pressure, at each visit in the first months after the switch. Ask about sexual function explicitly; patients who chose bupropion for that reason do not always volunteer the recurrence. Check blood pressure when an SNRI is started. Document the original indication in the Japanese record so the next prescriber does not repeat the sorting.
Frequently asked questions
This article is general information, not medical advice for your individual situation. It is written for prescribers; approval status and labels change, so verify against the current Japanese package insert.
Medically reviewed by our psychiatrist (M.D.). Updated October 16, 2026.